AlphAIalphai — Financial news for AI agents
yahoo.comAUG 64 min read$AHCO

AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance

AdaptHealth Corp. (NASDAQ:AHCO) shares fell about 13% premarket after Q2 2026 results missed expectations and the company cut full-year guidance. It reported a net loss of $0.99 per share and revenue of $740.3M versus $848.9M expected. FY revenue guidance was lowered to $2.85B-$2.89B from about $3.49B, with adjusted EBITDA $490M-$520M and free cash flow $80M-$120M.

Original reporting
yahoo.com
Published Aug 6, 2026, 1:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 1:57 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
AdaptHealth Shares Sink After Earnings Miss and Lower Full-Year Guidance — source image
Source · yahoo.com
Decision brief

The 30-second read

$AHCOBearishHigh
01

Why it matters

The combination of an earnings miss, large net loss driven by a goodwill impairment, and a broad guidance cut (revenue, adjusted EBITDA, and free cash flow) is likely to drive immediate repricing and heightened volatility.

02

Market read

Traders can act on a fresh earnings-and-guidance catalyst with explicit 2026 ranges and disclosed headwinds, explaining the pre-market selloff.

03

What to watch

The Diabetes Health business is classified as discontinued operations, so reported revenue comparisons and impairment effects may overstate ongoing operating weakness versus underlying continuing operations.

Relevance 9/10Novelty 9/10Timing: pre-market today after Q2 earnings and guidance cut

Background

AdaptHealth is a home medical equipment provider; the article centers on its Q2 2026 results, margin pressure, and a major guidance reduction for fiscal 2026.

Company-level read

Ticker impact

$AHCOBearishHigh confidence
Context

AdaptHealth (AHCO) shares fell nearly 13% pre-market after Q2 results missed expectations and full-year revenue, EBITDA, and FCF guidance were cut sharply.

Expected impact

Further downside volatility likely as investors reprice 2026 revenue, adjusted EBITDA, and free cash flow toward the lowered ranges.

Evidence & confidence

The article reports a clear earnings miss (loss vs EPS expectation, revenue miss) plus materially lower full-year guidance and specific headwinds (discontinued Diabetes business, contract impact, price increases, impairment).

Market effects

Sector

Signals pressure in home medical equipment reimbursement economics and margin durability, potentially weighing on sentiment for similar providers.

Regional

U.S. West Coast capitated contract impact is cited as a headwind, highlighting regional reimbursement variability.

Global

Primarily U.S.-focused healthcare services read-through; limited direct global impact.

Counterpoint

What could challenge this read

Management cites robust demand and record volume gains, suggesting the margin hit may be transition-related and could stabilize if execution improves.

Key entities

  • company
    AdaptHealth Corp.

    Home medical equipment provider reporting Q2 2026 results and cutting full-year guidance.

  • person
    Suzanne Foster

    CEO cited for comments on robust demand but margin pressure from transition complexity.

Read at source← All news

Related articles

AUG 15
$AHCOMedAI 8/10

AdaptHealth Cuts 2026 Outlook as Contract Costs Hit Margins

AdaptHealth Corp. (AHCO) cut its 2026 adjusted EBITDA outlook to $490 million to $520 million from $680 million to $730 million, citing margin pressure from West Coast capitated contract costs and a manufacturer price increase. Revenue guidance is $2.85 billion to $2.89 billion. Q2 organic revenue rose 15.9% to $740.3 million. The company agreed to sell Diabetes Health for $235 million.

mychesco.com6 min
AUG 11
$AHCOHighAI 9/10

AdaptHealth (AHCO) Q2 2026 Earnings Call Transcript

AdaptHealth (AHCO) reported Q2 2026 net revenue of $740.3 million, up 12.7% year over year, with organic revenue growth of 15.9%. Adjusted EBITDA was $132 million, down 3.2%, and full-year revenue guidance was cut to $2.85-$2.89 billion with adjusted EBITDA of $490-$520 million. The company cited West Coast contract costs and a $30 million supplier price headwind, plus a $235 million diabetes divestiture.

fool.com7 min
AUG 11
$AHCOMed

AdaptHealth Sells Diabetes Unit to Sharpen Focus on Sleep, Respiratory Growth

AdaptHealth (NASDAQ:AHCO) said it will sell its diabetes unit to focus on sleep and respiratory. The deal is expected to leave about $60 million of overhead costs in continuing operations, with roughly half removed in year one. Q2 revenue grew 16%, including West Coast expansion, while the company works on contract onboarding and supplier rebate terms.

yahoo.com6 min
AUG 9
$AHCOHighAI 9/10

Why AdaptHealth Stock Plummeted This Week

AdaptHealth (NASDAQ: AHCO) shares fell about 47% this week after the company reported Q2 results below expectations and issued sharply lower guidance. Analysts expected EPS of $0.15; AdaptHealth posted a loss of $1.07 per share. Sales rose 12.7% to $740.3M but missed forecasts. Full-year sales guidance was cut to $2.85B-$2.89B and EBITDA and FCF ranges were reduced.

yahoo.com2 min
AUG 4
$AHCOHighAI 9/10

Why AdaptHealth (AHCO) Stock Is Trading Lower Today

AdaptHealth Corp. (AHCO) shares fell about 39.5% after its Q2 results missed expectations and it cut full-year guidance. The company reported a GAAP loss of $0.99 per share versus a $0.15 gain estimate, and revenue of $740.3 million versus $847.2 million expected. It lowered 2026 revenue guidance midpoint to $2.87B from $3.49B and adjusted EBITDA to $490M-$520M, citing West Coast partnership issues and a manufacturer price increase.

financialcontent.com6 min